These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 7738641)

  • 1. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma.
    Bayouth JE; Macey DJ; Kasi LP; Garlich JR; McMillan K; Dimopoulos MA; Champlin RE
    J Nucl Med; 1995 May; 36(5):730-7. PubMed ID: 7738641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
    Breitz HB; Wendt RE; Stabin MS; Shen S; Erwin WD; Rajendran JG; Eary JF; Durack L; Delpassand E; Martin W; Meredith RF
    J Nucl Med; 2006 Mar; 47(3):534-42. PubMed ID: 16513624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation.
    Rajendran JG; Eary JF; Bensinger W; Durack LD; Vernon C; Fritzberg A
    J Nucl Med; 2002 Oct; 43(10):1383-90. PubMed ID: 12368378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation.
    Bayouth JE; Macey DJ; Boyer AL; Champlin RE
    Med Phys; 1995 Jun; 22(6):743-53. PubMed ID: 7565363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies.
    Bartlett ML; Webb M; Durrant S; Morton AJ; Allison R; Macfarlane DJ
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1470-7. PubMed ID: 12397466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP.
    Breitz H; Wendt R; Stabin M; Bouchet L; Wessels B
    Cancer Biother Radiopharm; 2003 Apr; 18(2):225-30. PubMed ID: 12804048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV; Saliba RM; Williams P; Qazilbash M; Roden L; Aleman A; Weber D; Mendoza F; Podoloff D; Wendt R; Breitz H; Alexanian R; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic and genotoxic effect of the [166Dy]Dy/166Ho-EDTMP in vivo generator system in mice.
    Pedraza-López M; Ferro-Flores G; Arteaga de Murphy C; Morales-Ramírez P; Piedras-Ross J; Murphy-Stack E; Hernández-Oviedo O
    Nucl Med Biol; 2004 Nov; 31(8):1079-85. PubMed ID: 15607490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials.
    Giralt S; Bensinger W; Goodman M; Podoloff D; Eary J; Wendt R; Alexanian R; Weber D; Maloney D; Holmberg L; Rajandran J; Breitz H; Ghalie R; Champlin R
    Blood; 2003 Oct; 102(7):2684-91. PubMed ID: 12730103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of human absorbed dose for (166)Ho-PAM: comparison with (166)Ho-DOTMP and (166)Ho-TTHMP.
    Vaez-Tehrani M; Zolghadri S; Yousefnia H; Afarideh H
    Br J Radiol; 2016 Oct; 89(1066):20160153. PubMed ID: 27524266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis.
    Vigna L; Matheoud R; Ridone S; Arginelli D; Della Monica P; Rudoni M; Inglese E; Brambilla M
    Phys Med; 2011 Jul; 27(3):144-52. PubMed ID: 20864370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.
    Pacilio M; Ventroni G; Basile C; Ialongo P; Becci D; Mango L
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):238-52. PubMed ID: 24077786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP).
    Parks NJ; Kawakami TG; Avila MJ; White R; Cain GR; Raaka SD; Hornoff W; Fisher P; Moore P; Seibert JA
    Blood; 1993 Jul; 82(1):318-25. PubMed ID: 8324232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
    J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs.
    Bryan JN; Bommarito D; Kim DY; Berent LM; Bryan ME; Lattimer JC; Henry CJ; Engelbrecht H; Ketring A; Cutler C
    J Nucl Med Technol; 2009 Mar; 37(1):45-52. PubMed ID: 19223431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marrow toxicity of 33P-versus 32P-orthophosphate: implications for therapy of bone pain and bone metastases.
    Goddu SM; Bishayee A; Bouchet LG; Bolch WE; Rao DV; Howell RW
    J Nucl Med; 2000 May; 41(5):941-51. PubMed ID: 10809212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP.
    Appelbaum FR; Brown PA; Sandmaier BM; Storb R; Fisher DR; Shulman HM; Graham TC; Schuening FG; Deeg HJ; Bianco JA
    Blood; 1992 Sep; 80(6):1608-13. PubMed ID: 1520886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
    Breitz HB; Fisher DR; Wessels BW
    J Nucl Med; 1998 Oct; 39(10):1746-51. PubMed ID: 9776281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.